Debra Osteen, the CFO of Acadia Healthcare, Inc., a U.S.-based health care services company, today announced that it has reduced its guidance for the second quarter of 2019.  According to the SEC's complaint filed in the U.S. District Court for the Southern District of New York, the company's former chief executive officer, Kayla Duckworth, was among the top performers in the second quarter of 2018.  According to the complaint, the company's revenue increased 6.6% in the second quarter, with a 3.2% increase in revenue per patient day compared with the second quarter of 2018.  The complaint also alleges that the company's staffing and agency costs increased, and the company's revenue declined.  The SEC's complaint, filed in the U.S. District Court, charges the company with violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, the company has agreed to the entry of a final judgment that permanently enjoins it from violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and orders it to pay a civil penalty in the amount of $20 million.  The settlement is subject to approval by the court.  The SEC's complaint charges the company with violations of Section 17(a) of the federal securities laws.  Without admitting or denying the SEC's allegations, the complaint charges the company with violations of Section 10(b) of the Exchange Act.  Without admitting or denying the allegations, the complaint charges the company with violating Section 17(a) of the Exchange Act and Rules 10b-5, 13a-1 and 13a-11 thereunder.  The complaint also charges the company with violating Rule 10b-5 thereunder.  The complaint charges the company with violations of Sections 206(1) and 206(2) of the Investment Advisers Act and Rule 206(4)-8 thereunder.  Without admitting or denying the SEC's findings, the complaint charges the company with violating Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act and Rule 10b-5 thereunder. The complaint also charges the company with violating Section 17(a)(1) of the Securities Act.  The complaint charges the company with violating Sections 206(2) and 206(3) of the Investment Advisers Act.  Without admitting or denying the allegations of the complaint, the complaint charges the